secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001654954-25-000570
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata and Revance enter clinical trial collaboration for Xyngari with Daxxify in hyperhidrosis
--------------------------------------------------------------------------------

- Dermata and Revance will collaborate on a Phase 2a trial of topical Xyngari with Daxxify for moderate-to-severe axillary hyperhidrosis.
- Trial expected to enroll ~48 patients across US sites; randomized 1:1:1:1, double-blind, placebo-controlled, 16-week evaluation.
- Primary endpoints: ≥50% reduction in gravimetric sweat, absolute change in sweat production, and sweat <50mg.
- If successful, parties may explore additional indications; Xyngari is currently in Phase 3 for acne; Daxxify approved for glabellar lines and cervical dystonia.
- Potential to be first approved needle-free intradermal delivery of a botulinum toxin product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425000570/0001654954-25-000570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425000570/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-000570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer